Table 5.

Summary of adverse events of JAKi from registered COVID-19 clinical trials.

Clinical trial identifier	JAKi	Subjects (case vs. control or case only)	Adverse event (case vs. control or case only)
NCT04421027	Baricitinib	n = 764 vs. n = 761	serious adverse events (15% vs.18%) serious infection (9% vs.10%) venous thromboembolic events (3% vs.3%) major adverse cardiovascular events (1% vs. 1%)
NCT04401579	Baricitinib	n = 515 vs. n = 518	serious adverse events (16% vs. 21%) new infections (5.9% vs. 11.2%)
NCT04338958	Ruxolitinib	n = 105	grade 3 liver toxicity (n = 1) anemia grade 3 (n = 2)
NCT04361903	Ruxolitinib	n = 18	no drug related adverse events were observed
NCT04359290	Ruxolitinib	n = 15	adverse event (n = 2)
ChiCTR2000029580	Ruxolitinib	n = 20 vs. n = 21	hematological adverse events (65% vs. 57.1%) serious adverse events (0 vs. 19%)